Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Free Cash Flow (2022 - 2025)

Axsome Therapeutics' Free Cash Flow history spans 4 years, with the latest figure at -$18.7 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 28.62% year-over-year to -$18.7 million; the TTM value through Dec 2025 reached -$93.9 million, up 27.04%, while the annual FY2025 figure was -$93.9 million, 27.04% up from the prior year.
  • Free Cash Flow for Q4 2025 was -$18.7 million at Axsome Therapeutics, down from $988000.0 in the prior quarter.
  • Across five years, Free Cash Flow topped out at $988000.0 in Q3 2025 and bottomed at -$55.5 million in Q2 2023.
  • The 4-year median for Free Cash Flow is -$30.3 million (2023), against an average of -$30.3 million.
  • The largest annual shift saw Free Cash Flow plummeted 809.11% in 2024 before it soared 105.28% in 2025.
  • A 4-year view of Free Cash Flow shows it stood at -$27.7 million in 2022, then decreased by 9.46% to -$30.4 million in 2023, then increased by 13.62% to -$26.2 million in 2024, then rose by 28.62% to -$18.7 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Free Cash Flow are -$18.7 million (Q4 2025), $988000.0 (Q3 2025), and -$32.4 million (Q2 2025).